SCHEMBL23498397

SCHEMBL23498397

CCOC(=O)c1c(C2CC2)cn(C)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
RECQL P46063 1/20 0.40
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK10 P53779 1/20 0.39
GAA P10253 4/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.38
BAZ2B Q9UIF8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21428171 0.78 KMT2A (0.47) KMT2AUSP2SMN1; SMN2MAPTCA12
SCHEMBL11212558 0.77 KMT2A (0.50) KMT2AUSP2SMN1; SMN2MAPTCA12
SCHEMBL23498583 0.76 CA12 (0.40) KMT2AUSP2SMN1; SMN2MAPTCA12
SCHEMBL23499036 0.76 KMT2A (0.49) KMT2AUSP2SMN1; SMN2MAPTCA12
SCHEMBL16740491 0.74 NPSR1 (0.43) KMT2ASMN1; SMN2MAPTGAALMNA
SCHEMBL23122058 0.74 LMNA (0.44) KMT2AUSP2SMN1; SMN2MAPTGAA
SCHEMBL4544319 0.74 MAPT (0.49) KMT2AUSP2SMN1; SMN2MAPTCA12
SCHEMBL16740490 0.74 TSHR (0.43) SMN1; SMN2CA12CA1CA2CA7
SCHEMBL31296900 0.72 LMNA (0.50) KMT2ASMN1; SMN2MAPTCA12CA1
SCHEMBL23498810 0.72 KMT2A (0.45) KMT2AUSP2SMN1; SMN2MAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230107941-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. 2023-04-06 US disclosed
WO-2021119081-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. (US) 2021-06-17 WO disclosed
WO-2021119081-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. (US) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107941-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS HAVCR2, COPB1, HDLBP KMT2A 4016/4885USP2 891/4885SMN1; SMN2 3117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.